NGENEBIO has a total of 18 patent applications. It increased the IP activity by 33.0%. Its first patent ever was published in 2016. It filed its patents most often in Republic of Korea, WIPO (World Intellectual Property Organization) and United States. Its main competitors in its focus markets biotechnology, computer technology and organic fine chemistry are AGILENT TECH BELGIUM NV, GUANGZHOU VISION GENE TECH CO LTD and BLUEGNOME LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Republic of Korea | 7 | |
#2 | WIPO (World Intellectual Property Organization) | 6 | |
#3 | United States | 3 | |
#4 | EPO (European Patent Office) | 1 | |
#5 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Computer technology | |
#3 | Organic fine chemistry | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Measuring microorganism processes | |
#2 | Bioinformatics | |
#3 | Combinatorial chemistry | |
#4 | Analysing materials | |
#5 | Electric digital data processing |
# | Name | Total Patents |
---|---|---|
#1 | Kim Kwang Joong | 15 |
#2 | Hong Chang Bum | 8 |
#3 | Oh Ensel | 6 |
#4 | Jung Jina | 4 |
#5 | Jung Kyongyong | 4 |
#6 | Lee Chang Seon | 3 |
#7 | Kim Si Eun | 3 |
#8 | Shin Young Kee | 3 |
#9 | Jeong Hae Min | 3 |
#10 | Lee Min Kyoung | 2 |
Publication | Filing date | Title |
---|---|---|
WO2020138995A1 | Method for analyzing y str loci of human subject by using multiplex system, and analysis kit using same | |
KR102042639B1 | Composition for detecting Mutation of BRCA1 and BRCA2 gene and use thereof | |
KR20190080223A | Method for Analysing Human Subject STR loci by using Dual Multiplex System and Kits using Thereof | |
KR101985864B1 | Composition for detecting Breast Cancer and Ovarian Cancer and uses thereof | |
KR101867011B1 | Method for detecting gene rearrangement using next generation sequencing | |
KR20190017161A | Method for increasing read data analysis accuracy in amplicon based NGS by using primer remover | |
KR20170127774A | Method for predicting prognosis of breast cancer patients using gene deletions as biomarkers |